Global Schizophrenia Treatments
Global Schizophrenia Treatments

Schizophrenia Treatments Comprehensive Study by Type (Medications, Conventional or Typical Antipsychotic Drugs, Atypical Antipsychotic Drugs, Therapies), End Users (Hospital Pharmacies, Drug Stores, Retail Pharmacies, E-Commerce), Treatment (Oral, Injectable), Therapeutic Class (Third-Generation Antipsychotics, Second-Generation Antipsychotics, Others) Players and Region - Global Market Outlook to 2026

Schizophrenia Treatments Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026 | CAGR: 4.25%  

May 2021 Edition 243 Pages 198 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Schizophrenia Treatments Market Overview:
Schizophrenia is a serious mental illness in which people have abnormal perceptions of reality. Schizophrenia may trigger hallucinations, delusions, and severely disordered perception and behavior, which can make it difficult to work on a daily basis. Delusions, hallucinations, disorganized perception, highly disorganized or unusual behavior, and diminished or loss of ability to function normally are some of the symptoms. As per sources, schizophrenia affects about 3.5 million people in the United States alone, with about 4,000 new cases identified per year. It is diagnosed 1.4 times more often in men than it is in women. It is diagnosed 1.4 times more frequently in males than females. The rising cases of schizophrenia in persons aging between 20–32 years will increase the demand for schizophrenia treatment globally. According to AMA, the Global Schizophrenia Treatments market is expected to see growth rate of 4.25%

Growth Drivers
  • Growing Burden Of Schizophrenia And Associated Disorders
  • Governments And Health Care Organizations Focus On Mental Health

Market Trends
  • Growing Occurrence in Male Aged between 20–28 years

Roadblocks
  • Risk of Drug Addiction

Opportunities
  • Increasing R&D Investments
  • High Demand Of Sophisticated Therapy By Physicians And Patients

Challenges
  • Patent Expiry of Major Drugs


Competitive Landscape:
Companies operating in the schizophrenia treatments market landscape should focus on mergers & acquisitions to improve their market share and overall position. Product launches, research, and expansion of the existing product portfolio are some of the other strategies that are being considered by key players to gain ground in the current schizophrenia treatments market.
Some of the key players profiled in the report are Johnson and Johnson (United States), Bristol-Myers Squibb (United States), Otsuka Pharmaceutical (Japan), AstraZeneca plc (United Kingdom), Sumitomo Dainippon Pharma (Japan), Eli Lilly and Company (United States), Alkermes plc (Ireland), Vanda Pharmaceuticals (United States), Allergan plc (Ireland) and Pfizer, Inc. (United States). Additionally, following companies can also be profiled that are part of our coverage like Gedeon Richter (Hungary), Merz Pharma GmbH & Co. KGaA (Germany) and Karuna Therapeutics (United States). Analyst at AMA Research see United States and European Players to retain maximum share of Global Schizophrenia Treatments market by 2026. Considering Market by End Users, the sub-segment i.e. Hospital Pharmacies will boost the Schizophrenia Treatments market. Considering Market by Treatment, the sub-segment i.e. Oral will boost the Schizophrenia Treatments market. Considering Market by Therapeutic Class, the sub-segment i.e. Third-Generation Antipsychotics will boost the Schizophrenia Treatments market.

What Can be Explored with the Schizophrenia Treatments Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Schizophrenia Treatments Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Schizophrenia Treatments
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Schizophrenia Treatments market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Schizophrenia Treatments market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes New Entrants/Investors, Analysts and Strategic Business Planners, Schizophrenia Treatments Providers, Venture Capitalists, Private Equity Firms, Government Regulatory and Research Organizations.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.
Report Objectives / Segmentation Covered
By Type
  • Medications
  • Conventional or Typical Antipsychotic Drugs
  • Atypical Antipsychotic Drugs
  • Therapies
By End Users
  • Hospital Pharmacies
  • Drug Stores
  • Retail Pharmacies
  • E-Commerce

By Treatment
  • Oral
  • Injectable

By Therapeutic Class
  • Third-Generation Antipsychotics
  • Second-Generation Antipsychotics
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Burden Of Schizophrenia And Associated Disorders
      • 3.2.2. Governments And Health Care Organizations Focus On Mental Health
    • 3.3. Market Challenges
      • 3.3.1. Patent Expiry of Major Drugs
    • 3.4. Market Trends
      • 3.4.1. Growing Occurrence in Male Aged between 20–28 years
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Schizophrenia Treatments, by Type, End Users, Treatment, Therapeutic Class and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Schizophrenia Treatments (Value)
      • 5.2.1. Global Schizophrenia Treatments by: Type (Value)
        • 5.2.1.1. Medications
        • 5.2.1.2. Conventional or Typical Antipsychotic Drugs
        • 5.2.1.3. Atypical Antipsychotic Drugs
        • 5.2.1.4. Therapies
      • 5.2.2. Global Schizophrenia Treatments by: End Users (Value)
        • 5.2.2.1. Hospital Pharmacies
        • 5.2.2.2. Drug Stores
        • 5.2.2.3. Retail Pharmacies
        • 5.2.2.4. E-Commerce
      • 5.2.3. Global Schizophrenia Treatments by: Treatment (Value)
        • 5.2.3.1. Oral
        • 5.2.3.2. Injectable
      • 5.2.4. Global Schizophrenia Treatments by: Therapeutic Class (Value)
        • 5.2.4.1. Third-Generation Antipsychotics
        • 5.2.4.2. Second-Generation Antipsychotics
        • 5.2.4.3. Others
      • 5.2.5. Global Schizophrenia Treatments Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Schizophrenia Treatments: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Johnson and Johnson (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bristol-Myers Squibb (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Otsuka Pharmaceutical (Japan)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. AstraZeneca plc (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Sumitomo Dainippon Pharma (Japan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Eli Lilly and Company (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Alkermes plc (Ireland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Vanda Pharmaceuticals (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Allergan plc (Ireland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Pfizer, Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Schizophrenia Treatments Sale, by Type, End Users, Treatment, Therapeutic Class and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Schizophrenia Treatments (Value)
      • 7.2.1. Global Schizophrenia Treatments by: Type (Value)
        • 7.2.1.1. Medications
        • 7.2.1.2. Conventional or Typical Antipsychotic Drugs
        • 7.2.1.3. Atypical Antipsychotic Drugs
        • 7.2.1.4. Therapies
      • 7.2.2. Global Schizophrenia Treatments by: End Users (Value)
        • 7.2.2.1. Hospital Pharmacies
        • 7.2.2.2. Drug Stores
        • 7.2.2.3. Retail Pharmacies
        • 7.2.2.4. E-Commerce
      • 7.2.3. Global Schizophrenia Treatments by: Treatment (Value)
        • 7.2.3.1. Oral
        • 7.2.3.2. Injectable
      • 7.2.4. Global Schizophrenia Treatments by: Therapeutic Class (Value)
        • 7.2.4.1. Third-Generation Antipsychotics
        • 7.2.4.2. Second-Generation Antipsychotics
        • 7.2.4.3. Others
      • 7.2.5. Global Schizophrenia Treatments Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Schizophrenia Treatments: by Type(USD Million)
  • Table 2. Schizophrenia Treatments Medications , by Region USD Million (2015-2020)
  • Table 3. Schizophrenia Treatments Conventional or Typical Antipsychotic Drugs , by Region USD Million (2015-2020)
  • Table 4. Schizophrenia Treatments Atypical Antipsychotic Drugs , by Region USD Million (2015-2020)
  • Table 5. Schizophrenia Treatments Therapies , by Region USD Million (2015-2020)
  • Table 6. Schizophrenia Treatments: by End Users(USD Million)
  • Table 7. Schizophrenia Treatments Hospital Pharmacies , by Region USD Million (2015-2020)
  • Table 8. Schizophrenia Treatments Drug Stores , by Region USD Million (2015-2020)
  • Table 9. Schizophrenia Treatments Retail Pharmacies , by Region USD Million (2015-2020)
  • Table 10. Schizophrenia Treatments E-Commerce , by Region USD Million (2015-2020)
  • Table 11. Schizophrenia Treatments: by Treatment(USD Million)
  • Table 12. Schizophrenia Treatments Oral , by Region USD Million (2015-2020)
  • Table 13. Schizophrenia Treatments Injectable , by Region USD Million (2015-2020)
  • Table 14. Schizophrenia Treatments: by Therapeutic Class(USD Million)
  • Table 15. Schizophrenia Treatments Third-Generation Antipsychotics , by Region USD Million (2015-2020)
  • Table 16. Schizophrenia Treatments Second-Generation Antipsychotics , by Region USD Million (2015-2020)
  • Table 17. Schizophrenia Treatments Others , by Region USD Million (2015-2020)
  • Table 18. South America Schizophrenia Treatments, by Country USD Million (2015-2020)
  • Table 19. South America Schizophrenia Treatments, by Type USD Million (2015-2020)
  • Table 20. South America Schizophrenia Treatments, by End Users USD Million (2015-2020)
  • Table 21. South America Schizophrenia Treatments, by Treatment USD Million (2015-2020)
  • Table 22. South America Schizophrenia Treatments, by Therapeutic Class USD Million (2015-2020)
  • Table 23. Brazil Schizophrenia Treatments, by Type USD Million (2015-2020)
  • Table 24. Brazil Schizophrenia Treatments, by End Users USD Million (2015-2020)
  • Table 25. Brazil Schizophrenia Treatments, by Treatment USD Million (2015-2020)
  • Table 26. Brazil Schizophrenia Treatments, by Therapeutic Class USD Million (2015-2020)
  • Table 27. Argentina Schizophrenia Treatments, by Type USD Million (2015-2020)
  • Table 28. Argentina Schizophrenia Treatments, by End Users USD Million (2015-2020)
  • Table 29. Argentina Schizophrenia Treatments, by Treatment USD Million (2015-2020)
  • Table 30. Argentina Schizophrenia Treatments, by Therapeutic Class USD Million (2015-2020)
  • Table 31. Rest of South America Schizophrenia Treatments, by Type USD Million (2015-2020)
  • Table 32. Rest of South America Schizophrenia Treatments, by End Users USD Million (2015-2020)
  • Table 33. Rest of South America Schizophrenia Treatments, by Treatment USD Million (2015-2020)
  • Table 34. Rest of South America Schizophrenia Treatments, by Therapeutic Class USD Million (2015-2020)
  • Table 35. Asia Pacific Schizophrenia Treatments, by Country USD Million (2015-2020)
  • Table 36. Asia Pacific Schizophrenia Treatments, by Type USD Million (2015-2020)
  • Table 37. Asia Pacific Schizophrenia Treatments, by End Users USD Million (2015-2020)
  • Table 38. Asia Pacific Schizophrenia Treatments, by Treatment USD Million (2015-2020)
  • Table 39. Asia Pacific Schizophrenia Treatments, by Therapeutic Class USD Million (2015-2020)
  • Table 40. China Schizophrenia Treatments, by Type USD Million (2015-2020)
  • Table 41. China Schizophrenia Treatments, by End Users USD Million (2015-2020)
  • Table 42. China Schizophrenia Treatments, by Treatment USD Million (2015-2020)
  • Table 43. China Schizophrenia Treatments, by Therapeutic Class USD Million (2015-2020)
  • Table 44. Japan Schizophrenia Treatments, by Type USD Million (2015-2020)
  • Table 45. Japan Schizophrenia Treatments, by End Users USD Million (2015-2020)
  • Table 46. Japan Schizophrenia Treatments, by Treatment USD Million (2015-2020)
  • Table 47. Japan Schizophrenia Treatments, by Therapeutic Class USD Million (2015-2020)
  • Table 48. India Schizophrenia Treatments, by Type USD Million (2015-2020)
  • Table 49. India Schizophrenia Treatments, by End Users USD Million (2015-2020)
  • Table 50. India Schizophrenia Treatments, by Treatment USD Million (2015-2020)
  • Table 51. India Schizophrenia Treatments, by Therapeutic Class USD Million (2015-2020)
  • Table 52. South Korea Schizophrenia Treatments, by Type USD Million (2015-2020)
  • Table 53. South Korea Schizophrenia Treatments, by End Users USD Million (2015-2020)
  • Table 54. South Korea Schizophrenia Treatments, by Treatment USD Million (2015-2020)
  • Table 55. South Korea Schizophrenia Treatments, by Therapeutic Class USD Million (2015-2020)
  • Table 56. Taiwan Schizophrenia Treatments, by Type USD Million (2015-2020)
  • Table 57. Taiwan Schizophrenia Treatments, by End Users USD Million (2015-2020)
  • Table 58. Taiwan Schizophrenia Treatments, by Treatment USD Million (2015-2020)
  • Table 59. Taiwan Schizophrenia Treatments, by Therapeutic Class USD Million (2015-2020)
  • Table 60. Australia Schizophrenia Treatments, by Type USD Million (2015-2020)
  • Table 61. Australia Schizophrenia Treatments, by End Users USD Million (2015-2020)
  • Table 62. Australia Schizophrenia Treatments, by Treatment USD Million (2015-2020)
  • Table 63. Australia Schizophrenia Treatments, by Therapeutic Class USD Million (2015-2020)
  • Table 64. Rest of Asia-Pacific Schizophrenia Treatments, by Type USD Million (2015-2020)
  • Table 65. Rest of Asia-Pacific Schizophrenia Treatments, by End Users USD Million (2015-2020)
  • Table 66. Rest of Asia-Pacific Schizophrenia Treatments, by Treatment USD Million (2015-2020)
  • Table 67. Rest of Asia-Pacific Schizophrenia Treatments, by Therapeutic Class USD Million (2015-2020)
  • Table 68. Europe Schizophrenia Treatments, by Country USD Million (2015-2020)
  • Table 69. Europe Schizophrenia Treatments, by Type USD Million (2015-2020)
  • Table 70. Europe Schizophrenia Treatments, by End Users USD Million (2015-2020)
  • Table 71. Europe Schizophrenia Treatments, by Treatment USD Million (2015-2020)
  • Table 72. Europe Schizophrenia Treatments, by Therapeutic Class USD Million (2015-2020)
  • Table 73. Germany Schizophrenia Treatments, by Type USD Million (2015-2020)
  • Table 74. Germany Schizophrenia Treatments, by End Users USD Million (2015-2020)
  • Table 75. Germany Schizophrenia Treatments, by Treatment USD Million (2015-2020)
  • Table 76. Germany Schizophrenia Treatments, by Therapeutic Class USD Million (2015-2020)
  • Table 77. France Schizophrenia Treatments, by Type USD Million (2015-2020)
  • Table 78. France Schizophrenia Treatments, by End Users USD Million (2015-2020)
  • Table 79. France Schizophrenia Treatments, by Treatment USD Million (2015-2020)
  • Table 80. France Schizophrenia Treatments, by Therapeutic Class USD Million (2015-2020)
  • Table 81. Italy Schizophrenia Treatments, by Type USD Million (2015-2020)
  • Table 82. Italy Schizophrenia Treatments, by End Users USD Million (2015-2020)
  • Table 83. Italy Schizophrenia Treatments, by Treatment USD Million (2015-2020)
  • Table 84. Italy Schizophrenia Treatments, by Therapeutic Class USD Million (2015-2020)
  • Table 85. United Kingdom Schizophrenia Treatments, by Type USD Million (2015-2020)
  • Table 86. United Kingdom Schizophrenia Treatments, by End Users USD Million (2015-2020)
  • Table 87. United Kingdom Schizophrenia Treatments, by Treatment USD Million (2015-2020)
  • Table 88. United Kingdom Schizophrenia Treatments, by Therapeutic Class USD Million (2015-2020)
  • Table 89. Netherlands Schizophrenia Treatments, by Type USD Million (2015-2020)
  • Table 90. Netherlands Schizophrenia Treatments, by End Users USD Million (2015-2020)
  • Table 91. Netherlands Schizophrenia Treatments, by Treatment USD Million (2015-2020)
  • Table 92. Netherlands Schizophrenia Treatments, by Therapeutic Class USD Million (2015-2020)
  • Table 93. Rest of Europe Schizophrenia Treatments, by Type USD Million (2015-2020)
  • Table 94. Rest of Europe Schizophrenia Treatments, by End Users USD Million (2015-2020)
  • Table 95. Rest of Europe Schizophrenia Treatments, by Treatment USD Million (2015-2020)
  • Table 96. Rest of Europe Schizophrenia Treatments, by Therapeutic Class USD Million (2015-2020)
  • Table 97. MEA Schizophrenia Treatments, by Country USD Million (2015-2020)
  • Table 98. MEA Schizophrenia Treatments, by Type USD Million (2015-2020)
  • Table 99. MEA Schizophrenia Treatments, by End Users USD Million (2015-2020)
  • Table 100. MEA Schizophrenia Treatments, by Treatment USD Million (2015-2020)
  • Table 101. MEA Schizophrenia Treatments, by Therapeutic Class USD Million (2015-2020)
  • Table 102. Middle East Schizophrenia Treatments, by Type USD Million (2015-2020)
  • Table 103. Middle East Schizophrenia Treatments, by End Users USD Million (2015-2020)
  • Table 104. Middle East Schizophrenia Treatments, by Treatment USD Million (2015-2020)
  • Table 105. Middle East Schizophrenia Treatments, by Therapeutic Class USD Million (2015-2020)
  • Table 106. Africa Schizophrenia Treatments, by Type USD Million (2015-2020)
  • Table 107. Africa Schizophrenia Treatments, by End Users USD Million (2015-2020)
  • Table 108. Africa Schizophrenia Treatments, by Treatment USD Million (2015-2020)
  • Table 109. Africa Schizophrenia Treatments, by Therapeutic Class USD Million (2015-2020)
  • Table 110. North America Schizophrenia Treatments, by Country USD Million (2015-2020)
  • Table 111. North America Schizophrenia Treatments, by Type USD Million (2015-2020)
  • Table 112. North America Schizophrenia Treatments, by End Users USD Million (2015-2020)
  • Table 113. North America Schizophrenia Treatments, by Treatment USD Million (2015-2020)
  • Table 114. North America Schizophrenia Treatments, by Therapeutic Class USD Million (2015-2020)
  • Table 115. United States Schizophrenia Treatments, by Type USD Million (2015-2020)
  • Table 116. United States Schizophrenia Treatments, by End Users USD Million (2015-2020)
  • Table 117. United States Schizophrenia Treatments, by Treatment USD Million (2015-2020)
  • Table 118. United States Schizophrenia Treatments, by Therapeutic Class USD Million (2015-2020)
  • Table 119. Canada Schizophrenia Treatments, by Type USD Million (2015-2020)
  • Table 120. Canada Schizophrenia Treatments, by End Users USD Million (2015-2020)
  • Table 121. Canada Schizophrenia Treatments, by Treatment USD Million (2015-2020)
  • Table 122. Canada Schizophrenia Treatments, by Therapeutic Class USD Million (2015-2020)
  • Table 123. Mexico Schizophrenia Treatments, by Type USD Million (2015-2020)
  • Table 124. Mexico Schizophrenia Treatments, by End Users USD Million (2015-2020)
  • Table 125. Mexico Schizophrenia Treatments, by Treatment USD Million (2015-2020)
  • Table 126. Mexico Schizophrenia Treatments, by Therapeutic Class USD Million (2015-2020)
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Schizophrenia Treatments: by Type(USD Million)
  • Table 138. Schizophrenia Treatments Medications , by Region USD Million (2021-2026)
  • Table 139. Schizophrenia Treatments Conventional or Typical Antipsychotic Drugs , by Region USD Million (2021-2026)
  • Table 140. Schizophrenia Treatments Atypical Antipsychotic Drugs , by Region USD Million (2021-2026)
  • Table 141. Schizophrenia Treatments Therapies , by Region USD Million (2021-2026)
  • Table 142. Schizophrenia Treatments: by End Users(USD Million)
  • Table 143. Schizophrenia Treatments Hospital Pharmacies , by Region USD Million (2021-2026)
  • Table 144. Schizophrenia Treatments Drug Stores , by Region USD Million (2021-2026)
  • Table 145. Schizophrenia Treatments Retail Pharmacies , by Region USD Million (2021-2026)
  • Table 146. Schizophrenia Treatments E-Commerce , by Region USD Million (2021-2026)
  • Table 147. Schizophrenia Treatments: by Treatment(USD Million)
  • Table 148. Schizophrenia Treatments Oral , by Region USD Million (2021-2026)
  • Table 149. Schizophrenia Treatments Injectable , by Region USD Million (2021-2026)
  • Table 150. Schizophrenia Treatments: by Therapeutic Class(USD Million)
  • Table 151. Schizophrenia Treatments Third-Generation Antipsychotics , by Region USD Million (2021-2026)
  • Table 152. Schizophrenia Treatments Second-Generation Antipsychotics , by Region USD Million (2021-2026)
  • Table 153. Schizophrenia Treatments Others , by Region USD Million (2021-2026)
  • Table 154. South America Schizophrenia Treatments, by Country USD Million (2021-2026)
  • Table 155. South America Schizophrenia Treatments, by Type USD Million (2021-2026)
  • Table 156. South America Schizophrenia Treatments, by End Users USD Million (2021-2026)
  • Table 157. South America Schizophrenia Treatments, by Treatment USD Million (2021-2026)
  • Table 158. South America Schizophrenia Treatments, by Therapeutic Class USD Million (2021-2026)
  • Table 159. Brazil Schizophrenia Treatments, by Type USD Million (2021-2026)
  • Table 160. Brazil Schizophrenia Treatments, by End Users USD Million (2021-2026)
  • Table 161. Brazil Schizophrenia Treatments, by Treatment USD Million (2021-2026)
  • Table 162. Brazil Schizophrenia Treatments, by Therapeutic Class USD Million (2021-2026)
  • Table 163. Argentina Schizophrenia Treatments, by Type USD Million (2021-2026)
  • Table 164. Argentina Schizophrenia Treatments, by End Users USD Million (2021-2026)
  • Table 165. Argentina Schizophrenia Treatments, by Treatment USD Million (2021-2026)
  • Table 166. Argentina Schizophrenia Treatments, by Therapeutic Class USD Million (2021-2026)
  • Table 167. Rest of South America Schizophrenia Treatments, by Type USD Million (2021-2026)
  • Table 168. Rest of South America Schizophrenia Treatments, by End Users USD Million (2021-2026)
  • Table 169. Rest of South America Schizophrenia Treatments, by Treatment USD Million (2021-2026)
  • Table 170. Rest of South America Schizophrenia Treatments, by Therapeutic Class USD Million (2021-2026)
  • Table 171. Asia Pacific Schizophrenia Treatments, by Country USD Million (2021-2026)
  • Table 172. Asia Pacific Schizophrenia Treatments, by Type USD Million (2021-2026)
  • Table 173. Asia Pacific Schizophrenia Treatments, by End Users USD Million (2021-2026)
  • Table 174. Asia Pacific Schizophrenia Treatments, by Treatment USD Million (2021-2026)
  • Table 175. Asia Pacific Schizophrenia Treatments, by Therapeutic Class USD Million (2021-2026)
  • Table 176. China Schizophrenia Treatments, by Type USD Million (2021-2026)
  • Table 177. China Schizophrenia Treatments, by End Users USD Million (2021-2026)
  • Table 178. China Schizophrenia Treatments, by Treatment USD Million (2021-2026)
  • Table 179. China Schizophrenia Treatments, by Therapeutic Class USD Million (2021-2026)
  • Table 180. Japan Schizophrenia Treatments, by Type USD Million (2021-2026)
  • Table 181. Japan Schizophrenia Treatments, by End Users USD Million (2021-2026)
  • Table 182. Japan Schizophrenia Treatments, by Treatment USD Million (2021-2026)
  • Table 183. Japan Schizophrenia Treatments, by Therapeutic Class USD Million (2021-2026)
  • Table 184. India Schizophrenia Treatments, by Type USD Million (2021-2026)
  • Table 185. India Schizophrenia Treatments, by End Users USD Million (2021-2026)
  • Table 186. India Schizophrenia Treatments, by Treatment USD Million (2021-2026)
  • Table 187. India Schizophrenia Treatments, by Therapeutic Class USD Million (2021-2026)
  • Table 188. South Korea Schizophrenia Treatments, by Type USD Million (2021-2026)
  • Table 189. South Korea Schizophrenia Treatments, by End Users USD Million (2021-2026)
  • Table 190. South Korea Schizophrenia Treatments, by Treatment USD Million (2021-2026)
  • Table 191. South Korea Schizophrenia Treatments, by Therapeutic Class USD Million (2021-2026)
  • Table 192. Taiwan Schizophrenia Treatments, by Type USD Million (2021-2026)
  • Table 193. Taiwan Schizophrenia Treatments, by End Users USD Million (2021-2026)
  • Table 194. Taiwan Schizophrenia Treatments, by Treatment USD Million (2021-2026)
  • Table 195. Taiwan Schizophrenia Treatments, by Therapeutic Class USD Million (2021-2026)
  • Table 196. Australia Schizophrenia Treatments, by Type USD Million (2021-2026)
  • Table 197. Australia Schizophrenia Treatments, by End Users USD Million (2021-2026)
  • Table 198. Australia Schizophrenia Treatments, by Treatment USD Million (2021-2026)
  • Table 199. Australia Schizophrenia Treatments, by Therapeutic Class USD Million (2021-2026)
  • Table 200. Rest of Asia-Pacific Schizophrenia Treatments, by Type USD Million (2021-2026)
  • Table 201. Rest of Asia-Pacific Schizophrenia Treatments, by End Users USD Million (2021-2026)
  • Table 202. Rest of Asia-Pacific Schizophrenia Treatments, by Treatment USD Million (2021-2026)
  • Table 203. Rest of Asia-Pacific Schizophrenia Treatments, by Therapeutic Class USD Million (2021-2026)
  • Table 204. Europe Schizophrenia Treatments, by Country USD Million (2021-2026)
  • Table 205. Europe Schizophrenia Treatments, by Type USD Million (2021-2026)
  • Table 206. Europe Schizophrenia Treatments, by End Users USD Million (2021-2026)
  • Table 207. Europe Schizophrenia Treatments, by Treatment USD Million (2021-2026)
  • Table 208. Europe Schizophrenia Treatments, by Therapeutic Class USD Million (2021-2026)
  • Table 209. Germany Schizophrenia Treatments, by Type USD Million (2021-2026)
  • Table 210. Germany Schizophrenia Treatments, by End Users USD Million (2021-2026)
  • Table 211. Germany Schizophrenia Treatments, by Treatment USD Million (2021-2026)
  • Table 212. Germany Schizophrenia Treatments, by Therapeutic Class USD Million (2021-2026)
  • Table 213. France Schizophrenia Treatments, by Type USD Million (2021-2026)
  • Table 214. France Schizophrenia Treatments, by End Users USD Million (2021-2026)
  • Table 215. France Schizophrenia Treatments, by Treatment USD Million (2021-2026)
  • Table 216. France Schizophrenia Treatments, by Therapeutic Class USD Million (2021-2026)
  • Table 217. Italy Schizophrenia Treatments, by Type USD Million (2021-2026)
  • Table 218. Italy Schizophrenia Treatments, by End Users USD Million (2021-2026)
  • Table 219. Italy Schizophrenia Treatments, by Treatment USD Million (2021-2026)
  • Table 220. Italy Schizophrenia Treatments, by Therapeutic Class USD Million (2021-2026)
  • Table 221. United Kingdom Schizophrenia Treatments, by Type USD Million (2021-2026)
  • Table 222. United Kingdom Schizophrenia Treatments, by End Users USD Million (2021-2026)
  • Table 223. United Kingdom Schizophrenia Treatments, by Treatment USD Million (2021-2026)
  • Table 224. United Kingdom Schizophrenia Treatments, by Therapeutic Class USD Million (2021-2026)
  • Table 225. Netherlands Schizophrenia Treatments, by Type USD Million (2021-2026)
  • Table 226. Netherlands Schizophrenia Treatments, by End Users USD Million (2021-2026)
  • Table 227. Netherlands Schizophrenia Treatments, by Treatment USD Million (2021-2026)
  • Table 228. Netherlands Schizophrenia Treatments, by Therapeutic Class USD Million (2021-2026)
  • Table 229. Rest of Europe Schizophrenia Treatments, by Type USD Million (2021-2026)
  • Table 230. Rest of Europe Schizophrenia Treatments, by End Users USD Million (2021-2026)
  • Table 231. Rest of Europe Schizophrenia Treatments, by Treatment USD Million (2021-2026)
  • Table 232. Rest of Europe Schizophrenia Treatments, by Therapeutic Class USD Million (2021-2026)
  • Table 233. MEA Schizophrenia Treatments, by Country USD Million (2021-2026)
  • Table 234. MEA Schizophrenia Treatments, by Type USD Million (2021-2026)
  • Table 235. MEA Schizophrenia Treatments, by End Users USD Million (2021-2026)
  • Table 236. MEA Schizophrenia Treatments, by Treatment USD Million (2021-2026)
  • Table 237. MEA Schizophrenia Treatments, by Therapeutic Class USD Million (2021-2026)
  • Table 238. Middle East Schizophrenia Treatments, by Type USD Million (2021-2026)
  • Table 239. Middle East Schizophrenia Treatments, by End Users USD Million (2021-2026)
  • Table 240. Middle East Schizophrenia Treatments, by Treatment USD Million (2021-2026)
  • Table 241. Middle East Schizophrenia Treatments, by Therapeutic Class USD Million (2021-2026)
  • Table 242. Africa Schizophrenia Treatments, by Type USD Million (2021-2026)
  • Table 243. Africa Schizophrenia Treatments, by End Users USD Million (2021-2026)
  • Table 244. Africa Schizophrenia Treatments, by Treatment USD Million (2021-2026)
  • Table 245. Africa Schizophrenia Treatments, by Therapeutic Class USD Million (2021-2026)
  • Table 246. North America Schizophrenia Treatments, by Country USD Million (2021-2026)
  • Table 247. North America Schizophrenia Treatments, by Type USD Million (2021-2026)
  • Table 248. North America Schizophrenia Treatments, by End Users USD Million (2021-2026)
  • Table 249. North America Schizophrenia Treatments, by Treatment USD Million (2021-2026)
  • Table 250. North America Schizophrenia Treatments, by Therapeutic Class USD Million (2021-2026)
  • Table 251. United States Schizophrenia Treatments, by Type USD Million (2021-2026)
  • Table 252. United States Schizophrenia Treatments, by End Users USD Million (2021-2026)
  • Table 253. United States Schizophrenia Treatments, by Treatment USD Million (2021-2026)
  • Table 254. United States Schizophrenia Treatments, by Therapeutic Class USD Million (2021-2026)
  • Table 255. Canada Schizophrenia Treatments, by Type USD Million (2021-2026)
  • Table 256. Canada Schizophrenia Treatments, by End Users USD Million (2021-2026)
  • Table 257. Canada Schizophrenia Treatments, by Treatment USD Million (2021-2026)
  • Table 258. Canada Schizophrenia Treatments, by Therapeutic Class USD Million (2021-2026)
  • Table 259. Mexico Schizophrenia Treatments, by Type USD Million (2021-2026)
  • Table 260. Mexico Schizophrenia Treatments, by End Users USD Million (2021-2026)
  • Table 261. Mexico Schizophrenia Treatments, by Treatment USD Million (2021-2026)
  • Table 262. Mexico Schizophrenia Treatments, by Therapeutic Class USD Million (2021-2026)
  • Table 263. Research Programs/Design for This Report
  • Table 264. Key Data Information from Secondary Sources
  • Table 265. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Schizophrenia Treatments: by Type USD Million (2015-2020)
  • Figure 5. Global Schizophrenia Treatments: by End Users USD Million (2015-2020)
  • Figure 6. Global Schizophrenia Treatments: by Treatment USD Million (2015-2020)
  • Figure 7. Global Schizophrenia Treatments: by Therapeutic Class USD Million (2015-2020)
  • Figure 8. South America Schizophrenia Treatments Share (%), by Country
  • Figure 9. Asia Pacific Schizophrenia Treatments Share (%), by Country
  • Figure 10. Europe Schizophrenia Treatments Share (%), by Country
  • Figure 11. MEA Schizophrenia Treatments Share (%), by Country
  • Figure 12. North America Schizophrenia Treatments Share (%), by Country
  • Figure 13. Global Schizophrenia Treatments share by Players 2020 (%)
  • Figure 14. Global Schizophrenia Treatments share by Players (Top 3) 2020(%)
  • Figure 15. Global Schizophrenia Treatments share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Johnson and Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 18. Johnson and Johnson (United States) Revenue: by Geography 2020
  • Figure 19. Bristol-Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 20. Bristol-Myers Squibb (United States) Revenue: by Geography 2020
  • Figure 21. Otsuka Pharmaceutical (Japan) Revenue, Net Income and Gross profit
  • Figure 22. Otsuka Pharmaceutical (Japan) Revenue: by Geography 2020
  • Figure 23. AstraZeneca plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 24. AstraZeneca plc (United Kingdom) Revenue: by Geography 2020
  • Figure 25. Sumitomo Dainippon Pharma (Japan) Revenue, Net Income and Gross profit
  • Figure 26. Sumitomo Dainippon Pharma (Japan) Revenue: by Geography 2020
  • Figure 27. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 28. Eli Lilly and Company (United States) Revenue: by Geography 2020
  • Figure 29. Alkermes plc (Ireland) Revenue, Net Income and Gross profit
  • Figure 30. Alkermes plc (Ireland) Revenue: by Geography 2020
  • Figure 31. Vanda Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 32. Vanda Pharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 33. Allergan plc (Ireland) Revenue, Net Income and Gross profit
  • Figure 34. Allergan plc (Ireland) Revenue: by Geography 2020
  • Figure 35. Pfizer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Pfizer, Inc. (United States) Revenue: by Geography 2020
  • Figure 37. Global Schizophrenia Treatments: by Type USD Million (2021-2026)
  • Figure 38. Global Schizophrenia Treatments: by End Users USD Million (2021-2026)
  • Figure 39. Global Schizophrenia Treatments: by Treatment USD Million (2021-2026)
  • Figure 40. Global Schizophrenia Treatments: by Therapeutic Class USD Million (2021-2026)
  • Figure 41. South America Schizophrenia Treatments Share (%), by Country
  • Figure 42. Asia Pacific Schizophrenia Treatments Share (%), by Country
  • Figure 43. Europe Schizophrenia Treatments Share (%), by Country
  • Figure 44. MEA Schizophrenia Treatments Share (%), by Country
  • Figure 45. North America Schizophrenia Treatments Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Johnson and Johnson (United States)
  • Bristol-Myers Squibb (United States)
  • Otsuka Pharmaceutical (Japan)
  • AstraZeneca plc (United Kingdom)
  • Sumitomo Dainippon Pharma (Japan)
  • Eli Lilly and Company (United States)
  • Alkermes plc (Ireland)
  • Vanda Pharmaceuticals (United States)
  • Allergan plc (Ireland)
  • Pfizer, Inc. (United States)
Additional players considered in the study are as follows:
Gedeon Richter (Hungary) , Merz Pharma GmbH & Co. KGaA (Germany) , Karuna Therapeutics (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation